Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Bennett

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Leukemia Research|August 19, 2003
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) studyAthena M Cherry, Stephanie R Brockman, Sarah F Paternoster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
Journal of Medicinal Chemistry|March 31, 2021
Structure-Activity Relationship of Heterocyclic P2Y<sub>14</sub> Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine BioisosteresYoung-Hwan Jung, Veronica Salmaso, Zhiwei Wen, et al.
Journal of Medicinal Chemistry|August 14, 2020
Exploration of Alternative Scaffolds for P2Y<sub>14</sub> Receptor Antagonists Containing a Biaryl CoreYoung-Hwan Jung, Jinha Yu, Zhiwei Wen, et al.
The New England Journal of Medicine|September 25, 2009
Anthracycline dose intensification in acute myeloid leukemiaHugo F Fernandez, Zhuoxin Sun, Xiaopan Yao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based reviewDenise M Oliansky, Joseph H Antin, John M Bennett, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
Leukemia Research|August 19, 2003
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) studyAthena M Cherry, Stephanie R Brockman, Sarah F Paternoster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
Journal of Medicinal Chemistry|March 31, 2021
Structure-Activity Relationship of Heterocyclic P2Y<sub>14</sub> Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine BioisosteresYoung-Hwan Jung, Veronica Salmaso, Zhiwei Wen, et al.
Journal of Medicinal Chemistry|August 14, 2020
Exploration of Alternative Scaffolds for P2Y<sub>14</sub> Receptor Antagonists Containing a Biaryl CoreYoung-Hwan Jung, Jinha Yu, Zhiwei Wen, et al.
The New England Journal of Medicine|September 25, 2009
Anthracycline dose intensification in acute myeloid leukemiaHugo F Fernandez, Zhuoxin Sun, Xiaopan Yao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based reviewDenise M Oliansky, Joseph H Antin, John M Bennett, et al.
Pageof 17